Kidney Renal Clear Cell Carcinoma: Correlation between gene mutation status and selected clinical features
Maintained by TCGA GDAC Team (Broad Institute/Dana-Farber Cancer Institute/Harvard Medical School)
Overview
Introduction

This pipeline computes the correlation between significantly recurrent gene mutations and selected clinical features.

Summary

Testing the association between mutation status of 98 genes and 9 clinical features across 293 patients, 3 significant findings detected with Q value < 0.25.

  • BAP1 mutation correlated to 'TUMOR.STAGE'.

  • NUDT11 mutation correlated to 'AGE'.

  • FBXO43 mutation correlated to 'Time to Death'.

Results
Overview of the results

Table 1.  Get Full Table Overview of the association between mutation status of 98 genes and 9 clinical features. Shown in the table are P values (Q values). Thresholded by Q value < 0.25, 3 significant findings detected.

Clinical
Features
Time
to
Death
AGE GENDER KARNOFSKY
PERFORMANCE
SCORE
PATHOLOGY
T
PATHOLOGY
N
PATHOLOGICSPREAD(M) TUMOR
STAGE
NEOADJUVANT
THERAPY
nMutated (%) nWild-Type logrank test t-test Fisher's exact test t-test Fisher's exact test Fisher's exact test Fisher's exact test Fisher's exact test Fisher's exact test
BAP1 27 (9%) 266 0.0131
(1.00)
0.828
(1.00)
0.00961
(1.00)
0.00295
(1.00)
0.627
(1.00)
0.000895
(0.691)
0.000111
(0.0858)
0.253
(1.00)
NUDT11 3 (1%) 290 0.6
(1.00)
1.58e-24
(1.23e-21)
0.554
(1.00)
0.718
(1.00)
1
(1.00)
0.479
(1.00)
1
(1.00)
FBXO43 5 (2%) 288 1.27e-13
(9.87e-11)
0.621
(1.00)
1
(1.00)
0.446
(1.00)
1
(1.00)
0.513
(1.00)
1
(1.00)
1
(1.00)
VHL 146 (50%) 147 0.82
(1.00)
0.0114
(1.00)
0.0868
(1.00)
0.359
(1.00)
0.438
(1.00)
0.76
(1.00)
0.731
(1.00)
0.509
(1.00)
1
(1.00)
KDM5C 18 (6%) 275 0.0803
(1.00)
0.206
(1.00)
0.00486
(1.00)
0.622
(1.00)
0.516
(1.00)
1
(1.00)
0.856
(1.00)
1
(1.00)
PBRM1 98 (33%) 195 0.444
(1.00)
0.339
(1.00)
0.0698
(1.00)
0.35
(1.00)
0.731
(1.00)
1
(1.00)
0.201
(1.00)
0.218
(1.00)
0.26
(1.00)
RRAD 4 (1%) 289 0.0836
(1.00)
0.806
(1.00)
0.123
(1.00)
0.0613
(1.00)
0.211
(1.00)
0.437
(1.00)
0.0702
(1.00)
1
(1.00)
SV2C 3 (1%) 290 0.731
(1.00)
0.0205
(1.00)
1
(1.00)
1
(1.00)
1
(1.00)
1
(1.00)
1
(1.00)
1
(1.00)
TOR1A 3 (1%) 290 0.0532
(1.00)
0.704
(1.00)
1
(1.00)
1
(1.00)
0.0753
(1.00)
1
(1.00)
1
(1.00)
1
(1.00)
SETD2 32 (11%) 261 0.949
(1.00)
0.11
(1.00)
0.244
(1.00)
0.229
(1.00)
0.605
(1.00)
0.0519
(1.00)
0.184
(1.00)
0.294
(1.00)
PTEN 15 (5%) 278 0.87
(1.00)
0.104
(1.00)
1
(1.00)
0.489
(1.00)
0.0657
(1.00)
1
(1.00)
0.592
(1.00)
0.146
(1.00)
PIK3CA 14 (5%) 279 0.797
(1.00)
0.387
(1.00)
0.57
(1.00)
0.152
(1.00)
0.555
(1.00)
1
(1.00)
0.251
(1.00)
1
(1.00)
STAG3L2 6 (2%) 287 0.252
(1.00)
0.115
(1.00)
1
(1.00)
0.415
(1.00)
1
(1.00)
0.579
(1.00)
0.334
(1.00)
1
(1.00)
MTOR 24 (8%) 269 0.123
(1.00)
0.203
(1.00)
0.119
(1.00)
0.298
(1.00)
0.0602
(1.00)
1
(1.00)
0.346
(1.00)
1
(1.00)
EBPL 6 (2%) 287 0.48
(1.00)
0.527
(1.00)
0.00161
(1.00)
0.117
(1.00)
1
(1.00)
1
(1.00)
0.0646
(1.00)
1
(1.00)
KANK3 6 (2%) 287 0.733
(1.00)
0.513
(1.00)
1
(1.00)
0.51
(1.00)
1
(1.00)
1
(1.00)
0.696
(1.00)
1
(1.00)
ANKRD36 10 (3%) 283 0.284
(1.00)
0.339
(1.00)
1
(1.00)
0.391
(1.00)
1
(1.00)
1
(1.00)
0.637
(1.00)
1
(1.00)
ZCCHC3 3 (1%) 290 0.392
(1.00)
0.829
(1.00)
0.554
(1.00)
0.374
(1.00)
1
(1.00)
1
(1.00)
0.811
(1.00)
1
(1.00)
FAM174B 3 (1%) 290 0.476
(1.00)
0.668
(1.00)
1
(1.00)
0.0917
(1.00)
1
(1.00)
0.0724
(1.00)
1
(1.00)
TSPAN19 4 (1%) 289 0.319
(1.00)
0.467
(1.00)
1
(1.00)
0.458
(1.00)
1
(1.00)
0.437
(1.00)
0.223
(1.00)
1
(1.00)
DACH2 7 (2%) 286 0.972
(1.00)
0.7
(1.00)
0.242
(1.00)
1
(1.00)
0.328
(1.00)
0.236
(1.00)
0.631
(1.00)
0.0702
(1.00)
KRTAP1-1 3 (1%) 290 0.296
(1.00)
0.97
(1.00)
0.0414
(1.00)
0.0917
(1.00)
0.35
(1.00)
0.146
(1.00)
1
(1.00)
UQCRFS1 3 (1%) 290 0.321
(1.00)
0.518
(1.00)
0.278
(1.00)
0.0452
(1.00)
1
(1.00)
1
(1.00)
0.0554
(1.00)
1
(1.00)
VCX2 3 (1%) 290 0.293
(1.00)
0.058
(1.00)
1
(1.00)
0.143
(1.00)
1
(1.00)
0.35
(1.00)
0.117
(1.00)
1
(1.00)
CR1 11 (4%) 282 0.582
(1.00)
0.936
(1.00)
0.523
(1.00)
0.831
(1.00)
1
(1.00)
0.645
(1.00)
0.692
(1.00)
1
(1.00)
KRT1 5 (2%) 288 0.00506
(1.00)
0.0322
(1.00)
0.346
(1.00)
0.172
(1.00)
1
(1.00)
1
(1.00)
0.072
(1.00)
1
(1.00)
ABCB1 8 (3%) 285 0.116
(1.00)
0.582
(1.00)
0.718
(1.00)
0.882
(1.00)
1
(1.00)
0.603
(1.00)
0.784
(1.00)
1
(1.00)
MADCAM1 4 (1%) 289 0.357
(1.00)
0.751
(1.00)
0.123
(1.00)
0.0204
(1.00)
1
(1.00)
0.0871
(1.00)
0.00475
(1.00)
1
(1.00)
WDR52 9 (3%) 284 0.967
(1.00)
0.395
(1.00)
0.724
(1.00)
0.647
(1.00)
1
(1.00)
0.342
(1.00)
0.842
(1.00)
1
(1.00)
TPTE2 7 (2%) 286 0.3
(1.00)
0.309
(1.00)
1
(1.00)
0.48
(1.00)
1
(1.00)
0.599
(1.00)
0.596
(1.00)
1
(1.00)
OR5H1 4 (1%) 289 0.919
(1.00)
0.524
(1.00)
0.612
(1.00)
0.606
(1.00)
1
(1.00)
1
(1.00)
0.67
(1.00)
1
(1.00)
PCDHGA8 4 (1%) 289 0.251
(1.00)
0.207
(1.00)
1
(1.00)
1
(1.00)
1
(1.00)
1
(1.00)
0.768
(1.00)
1
(1.00)
POLDIP2 4 (1%) 289 0.458
(1.00)
0.705
(1.00)
1
(1.00)
0.458
(1.00)
1
(1.00)
0.437
(1.00)
0.357
(1.00)
1
(1.00)
CCNB2 5 (2%) 288 0.784
(1.00)
0.459
(1.00)
1
(1.00)
1
(1.00)
1
(1.00)
1
(1.00)
0.911
(1.00)
1
(1.00)
NFE2L2 5 (2%) 288 0.163
(1.00)
0.162
(1.00)
1
(1.00)
0.827
(1.00)
1
(1.00)
0.513
(1.00)
0.619
(1.00)
1
(1.00)
BAGE2 4 (1%) 289 0.961
(1.00)
0.667
(1.00)
0.612
(1.00)
0.796
(1.00)
1
(1.00)
1
(1.00)
0.589
(1.00)
1
(1.00)
RECQL5 6 (2%) 287 0.0507
(1.00)
0.575
(1.00)
0.188
(1.00)
0.607
(1.00)
0.328
(1.00)
0.183
(1.00)
0.359
(1.00)
1
(1.00)
SCAI 7 (2%) 286 0.461
(1.00)
0.583
(1.00)
0.428
(1.00)
0.246
(1.00)
1
(1.00)
0.599
(1.00)
0.793
(1.00)
1
(1.00)
GFRAL 5 (2%) 288 0.655
(1.00)
0.0399
(1.00)
1
(1.00)
0.096
(1.00)
1
(1.00)
1
(1.00)
0.288
(1.00)
1
(1.00)
NPNT 6 (2%) 287 0.0806
(1.00)
0.222
(1.00)
0.668
(1.00)
0.342
(1.00)
1
(1.00)
1
(1.00)
0.219
(1.00)
1
(1.00)
MSN 4 (1%) 289 0.63
(1.00)
0.578
(1.00)
1
(1.00)
0.19
(1.00)
1
(1.00)
1
(1.00)
0.464
(1.00)
1
(1.00)
CNTNAP4 9 (3%) 284 0.485
(1.00)
0.5
(1.00)
0.724
(1.00)
0.51
(1.00)
1
(1.00)
1
(1.00)
0.513
(1.00)
1
(1.00)
GRIN2B 11 (4%) 282 0.952
(1.00)
0.755
(1.00)
1
(1.00)
0.831
(1.00)
1
(1.00)
1
(1.00)
0.587
(1.00)
1
(1.00)
DNAH9 17 (6%) 276 0.535
(1.00)
0.986
(1.00)
0.3
(1.00)
0.783
(1.00)
0.516
(1.00)
0.71
(1.00)
0.592
(1.00)
1
(1.00)
SP8 3 (1%) 290 0.252
(1.00)
0.0518
(1.00)
1
(1.00)
1
(1.00)
1
(1.00)
1
(1.00)
1
(1.00)
1
(1.00)
ZNF800 6 (2%) 287 0.166
(1.00)
0.599
(1.00)
1
(1.00)
1
(1.00)
1
(1.00)
0.579
(1.00)
0.806
(1.00)
1
(1.00)
SFRS15 9 (3%) 284 0.564
(1.00)
0.804
(1.00)
0.724
(1.00)
0.647
(1.00)
1
(1.00)
1
(1.00)
0.459
(1.00)
1
(1.00)
UGT2A3 4 (1%) 289 0.529
(1.00)
0.354
(1.00)
0.612
(1.00)
1
(1.00)
1
(1.00)
0.0871
(1.00)
0.189
(1.00)
1
(1.00)
LPAR4 4 (1%) 289 0.534
(1.00)
0.457
(1.00)
0.612
(1.00)
1
(1.00)
1
(1.00)
1
(1.00)
0.768
(1.00)
1
(1.00)
SPAM1 5 (2%) 288 0.27
(1.00)
0.192
(1.00)
0.661
(1.00)
0.096
(1.00)
1
(1.00)
1
(1.00)
0.288
(1.00)
1
(1.00)
LMO4 3 (1%) 290 0.902
(1.00)
0.0752
(1.00)
1
(1.00)
0.519
(1.00)
1
(1.00)
1
(1.00)
0.38
(1.00)
1
(1.00)
RNF115 4 (1%) 289 0.611
(1.00)
0.727
(1.00)
0.612
(1.00)
0.796
(1.00)
1
(1.00)
1
(1.00)
1
(1.00)
1
(1.00)
ZYG11B 6 (2%) 287 0.317
(1.00)
0.00367
(1.00)
1
(1.00)
0.863
(1.00)
1
(1.00)
1
(1.00)
0.864
(1.00)
1
(1.00)
MARCKS 3 (1%) 290 0.298
(1.00)
0.113
(1.00)
0.278
(1.00)
0.0917
(1.00)
1
(1.00)
1
(1.00)
0.0724
(1.00)
1
(1.00)
NBPF10 20 (7%) 273 0.237
(1.00)
0.321
(1.00)
0.151
(1.00)
0.202
(1.00)
0.139
(1.00)
0.0353
(1.00)
0.134
(1.00)
1
(1.00)
WASL 5 (2%) 288 0.612
(1.00)
0.225
(1.00)
0.346
(1.00)
0.325
(1.00)
1
(1.00)
1
(1.00)
0.083
(1.00)
1
(1.00)
PRB3 3 (1%) 290 0.123
(1.00)
0.554
(1.00)
1
(1.00)
0.0753
(1.00)
1
(1.00)
1
(1.00)
1
(1.00)
MED12L 8 (3%) 285 0.018
(1.00)
0.875
(1.00)
1
(1.00)
0.882
(1.00)
1
(1.00)
0.289
(1.00)
0.625
(1.00)
1
(1.00)
NF2 6 (2%) 287 0.424
(1.00)
0.853
(1.00)
0.423
(1.00)
0.177
(1.00)
0.271
(1.00)
0.579
(1.00)
0.203
(1.00)
1
(1.00)
PRB4 3 (1%) 290 0.71
(1.00)
0.0414
(1.00)
0.519
(1.00)
1
(1.00)
1
(1.00)
0.38
(1.00)
1
(1.00)
KCNH7 8 (3%) 285 0.787
(1.00)
0.95
(1.00)
1
(1.00)
0.529
(1.00)
0.211
(1.00)
0.603
(1.00)
0.715
(1.00)
1
(1.00)
TP53 9 (3%) 284 0.0454
(1.00)
0.091
(1.00)
0.285
(1.00)
0.032
(1.00)
0.328
(1.00)
1
(1.00)
0.0461
(1.00)
1
(1.00)
PRIM2 5 (2%) 288 0.105
(1.00)
0.796
(1.00)
0.346
(1.00)
0.096
(1.00)
1
(1.00)
1
(1.00)
0.288
(1.00)
1
(1.00)
PTPN18 4 (1%) 289 0.416
(1.00)
0.349
(1.00)
1
(1.00)
0.258
(1.00)
1
(1.00)
1
(1.00)
0.407
(1.00)
1
(1.00)
SLC2A14 3 (1%) 290 0.713
(1.00)
0.897
(1.00)
1
(1.00)
0.519
(1.00)
1
(1.00)
1
(1.00)
0.38
(1.00)
1
(1.00)
DPP10 6 (2%) 287 0.369
(1.00)
0.902
(1.00)
1
(1.00)
0.225
(1.00)
1
(1.00)
0.183
(1.00)
1
(1.00)
1
(1.00)
OR10G7 5 (2%) 288 0.0498
(1.00)
0.301
(1.00)
1
(1.00)
0.568
(1.00)
1
(1.00)
0.513
(1.00)
0.0542
(1.00)
1
(1.00)
ZKSCAN1 4 (1%) 289 0.558
(1.00)
0.675
(1.00)
0.612
(1.00)
0.19
(1.00)
1
(1.00)
1
(1.00)
0.464
(1.00)
1
(1.00)
MYO6 3 (1%) 290 0.196
(1.00)
0.554
(1.00)
0.374
(1.00)
1
(1.00)
0.811
(1.00)
1
(1.00)
MAGEC1 7 (2%) 286 0.586
(1.00)
0.194
(1.00)
0.242
(1.00)
0.878
(1.00)
0.328
(1.00)
0.599
(1.00)
0.198
(1.00)
1
(1.00)
KRTAP4-1 3 (1%) 290 0.927
(1.00)
0.173
(1.00)
0.0414
(1.00)
0.718
(1.00)
1
(1.00)
1
(1.00)
0.479
(1.00)
1
(1.00)
POTEC 10 (3%) 283 0.386
(1.00)
0.0352
(1.00)
1
(1.00)
0.81
(1.00)
1
(1.00)
1
(1.00)
0.753
(1.00)
1
(1.00)
RPUSD2 3 (1%) 290 0.789
(1.00)
1
(1.00)
1
(1.00)
1
(1.00)
1
(1.00)
1
(1.00)
1
(1.00)
SERPINB5 3 (1%) 290 0.764
(1.00)
0.765
(1.00)
0.554
(1.00)
0.374
(1.00)
1
(1.00)
1
(1.00)
0.811
(1.00)
1
(1.00)
ADCY8 5 (2%) 288 0.706
(1.00)
0.582
(1.00)
0.167
(1.00)
0.262
(1.00)
0.0753
(1.00)
0.513
(1.00)
0.0946
(1.00)
1
(1.00)
COL11A1 8 (3%) 285 0.946
(1.00)
0.546
(1.00)
0.269
(1.00)
0.783
(1.00)
0.271
(1.00)
0.603
(1.00)
0.596
(1.00)
1
(1.00)
CLYBL 4 (1%) 289 0.375
(1.00)
0.646
(1.00)
0.302
(1.00)
0.124
(1.00)
1
(1.00)
1
(1.00)
0.128
(1.00)
1
(1.00)
SPEN 14 (5%) 279 0.312
(1.00)
0.561
(1.00)
1
(1.00)
0.632
(1.00)
0.139
(1.00)
0.702
(1.00)
0.6
(1.00)
1
(1.00)
MSR1 5 (2%) 288 0.156
(1.00)
0.353
(1.00)
1
(1.00)
0.325
(1.00)
0.0286
(1.00)
0.513
(1.00)
0.107
(1.00)
1
(1.00)
ADAMTS20 7 (2%) 286 0.163
(1.00)
0.243
(1.00)
0.698
(1.00)
0.878
(1.00)
1
(1.00)
0.0523
(1.00)
0.0781
(1.00)
1
(1.00)
C15ORF26 4 (1%) 289 0.221
(1.00)
0.0652
(1.00)
0.302
(1.00)
0.458
(1.00)
0.0871
(1.00)
0.189
(1.00)
1
(1.00)
ZFP112 5 (2%) 288 0.363
(1.00)
0.876
(1.00)
0.167
(1.00)
0.446
(1.00)
1
(1.00)
1
(1.00)
0.831
(1.00)
1
(1.00)
CLN8 3 (1%) 290 0.47
(1.00)
0.193
(1.00)
0.278
(1.00)
0.374
(1.00)
1
(1.00)
1
(1.00)
0.811
(1.00)
1
(1.00)
RARA 4 (1%) 289 0.462
(1.00)
0.554
(1.00)
1
(1.00)
0.606
(1.00)
1
(1.00)
1
(1.00)
0.67
(1.00)
1
(1.00)
LILRB3 3 (1%) 290 0.803
(1.00)
0.92
(1.00)
0.278
(1.00)
0.244
(1.00)
0.35
(1.00)
0.583
(1.00)
1
(1.00)
TMEM184C 4 (1%) 289 0.0172
(1.00)
0.000391
(0.302)
1
(1.00)
0.796
(1.00)
1
(1.00)
1
(1.00)
1
(1.00)
1
(1.00)
STAG2 10 (3%) 283 0.951
(1.00)
0.00867
(1.00)
1
(1.00)
0.0727
(1.00)
1
(1.00)
1
(1.00)
0.0782
(1.00)
1
(1.00)
SPRYD5 4 (1%) 289 0.516
(1.00)
0.454
(1.00)
1
(1.00)
0.606
(1.00)
1
(1.00)
1
(1.00)
0.67
(1.00)
1
(1.00)
SDR16C5 4 (1%) 289 0.825
(1.00)
0.323
(1.00)
0.302
(1.00)
1
(1.00)
1
(1.00)
0.0871
(1.00)
0.189
(1.00)
1
(1.00)
DSCR6 3 (1%) 290 0.878
(1.00)
0.828
(1.00)
0.278
(1.00)
0.718
(1.00)
1
(1.00)
0.35
(1.00)
0.694
(1.00)
1
(1.00)
RALGAPA1 7 (2%) 286 0.909
(1.00)
0.71
(1.00)
0.428
(1.00)
0.0809
(1.00)
1
(1.00)
1
(1.00)
0.0588
(1.00)
1
(1.00)
KRTAP4-9 3 (1%) 290 0.473
(1.00)
0.545
(1.00)
1
(1.00)
0.374
(1.00)
1
(1.00)
1
(1.00)
0.811
(1.00)
1
(1.00)
COL4A5 7 (2%) 286 0.114
(1.00)
0.641
(1.00)
0.0522
(1.00)
0.351
(1.00)
0.0149
(1.00)
1
(1.00)
0.47
(1.00)
1
(1.00)
POLR3B 4 (1%) 289 0.896
(1.00)
0.577
(1.00)
0.612
(1.00)
0.796
(1.00)
0.145
(1.00)
1
(1.00)
0.589
(1.00)
1
(1.00)
EMR3 6 (2%) 287 0.631
(1.00)
0.0587
(1.00)
1
(1.00)
0.117
(1.00)
1
(1.00)
0.579
(1.00)
0.112
(1.00)
1
(1.00)
BZW2 3 (1%) 290 0.903
(1.00)
0.773
(1.00)
0.278
(1.00)
0.244
(1.00)
1
(1.00)
1
(1.00)
0.583
(1.00)
1
(1.00)
OMD 3 (1%) 290 0.0135
(1.00)
0.0458
(1.00)
1
(1.00)
0.0917
(1.00)
0.145
(1.00)
0.35
(1.00)
0.0393
(1.00)
1
(1.00)
PCDH10 6 (2%) 287 0.685
(1.00)
0.166
(1.00)
0.668
(1.00)
0.732
(1.00)
1
(1.00)
0.579
(1.00)
1
(1.00)
1
(1.00)
'BAP1 MUTATION STATUS' versus 'TUMOR.STAGE'

P value = 0.000111 (Fisher's exact test), Q value = 0.086

Table S1.  Gene #7: 'BAP1 MUTATION STATUS' versus Clinical Feature #8: 'TUMOR.STAGE'

nPatients I II III IV
ALL 144 31 76 42
BAP1 MUTATED 5 5 6 11
BAP1 WILD-TYPE 139 26 70 31

Figure S1.  Get High-res Image Gene #7: 'BAP1 MUTATION STATUS' versus Clinical Feature #8: 'TUMOR.STAGE'

'NUDT11 MUTATION STATUS' versus 'AGE'

P value = 1.58e-24 (t-test), Q value = 1.2e-21

Table S2.  Gene #15: 'NUDT11 MUTATION STATUS' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 293 60.3 (11.9)
NUDT11 MUTATED 3 74.7 (0.6)
NUDT11 WILD-TYPE 290 60.2 (11.9)

Figure S2.  Get High-res Image Gene #15: 'NUDT11 MUTATION STATUS' versus Clinical Feature #2: 'AGE'

'FBXO43 MUTATION STATUS' versus 'Time to Death'

P value = 1.27e-13 (logrank test), Q value = 9.9e-11

Table S3.  Gene #60: 'FBXO43 MUTATION STATUS' versus Clinical Feature #1: 'Time to Death'

nPatients nDeath Duration Range (Median), Month
ALL 291 77 0.1 - 109.6 (34.3)
FBXO43 MUTATED 5 3 1.6 - 10.8 (1.8)
FBXO43 WILD-TYPE 286 74 0.1 - 109.6 (34.9)

Figure S3.  Get High-res Image Gene #60: 'FBXO43 MUTATION STATUS' versus Clinical Feature #1: 'Time to Death'

Methods & Data
Input
  • Mutation data file = KIRC.mutsig.cluster.txt

  • Clinical data file = KIRC.clin.merged.picked.txt

  • Number of patients = 293

  • Number of significantly mutated genes = 98

  • Number of selected clinical features = 9

  • Exclude genes that fewer than K tumors have mutations, K = 3

Survival analysis

For survival clinical features, the Kaplan-Meier survival curves of tumors with and without gene mutations were plotted and the statistical significance P values were estimated by logrank test (Bland and Altman 2004) using the 'survdiff' function in R

Student's t-test analysis

For continuous numerical clinical features, two-tailed Student's t test with unequal variance (Lehmann and Romano 2005) was applied to compare the clinical values between tumors with and without gene mutations using 't.test' function in R

Fisher's exact test

For binary or multi-class clinical features (nominal or ordinal), two-tailed Fisher's exact tests (Fisher 1922) were used to estimate the P values using the 'fisher.test' function in R

Q value calculation

For multiple hypothesis correction, Q value is the False Discovery Rate (FDR) analogue of the P value (Benjamini and Hochberg 1995), defined as the minimum FDR at which the test may be called significant. We used the 'Benjamini and Hochberg' method of 'p.adjust' function in R to convert P values into Q values.

Download Results

This is an experimental feature. The full results of the analysis summarized in this report can be downloaded from the TCGA Data Coordination Center.

References
[1] Bland and Altman, Statistics notes: The logrank test, BMJ 328(7447):1073 (2004)
[2] Lehmann and Romano, Testing Statistical Hypotheses (3E ed.), New York: Springer. ISBN 0387988645 (2005)
[3] Fisher, R.A., On the interpretation of chi-square from contingency tables, and the calculation of P, Journal of the Royal Statistical Society 85(1):87-94 (1922)
[4] Benjamini and Hochberg, Controlling the false discovery rate: a practical and powerful approach to multiple testing, Journal of the Royal Statistical Society Series B 59:289-300 (1995)